Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that ...

Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...

Moderna (MRNA) stock drops even after beating Q2 2025 forecasts, as it lowered the top end of the revenue outlook due to ...